Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

Mazor, Ronit; King, Emily; Pastan, Ira

Mazor, Ronit; King, Emily; Pastan, Ira.

Afiliación

Mazor R; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. Electronic address: mazorr@Medimmune.com.
King E; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.
Pastan I; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. Electronic address: pastani@mail.nih.gov.

Cell Immunol ; 334: 38-41, 2018 12.

Article en En | MEDLINE | ID: mdl-30213644

Asunto(s)

Anticuerpos Monoclonales/inmunología; Antígeno B7-H1/inmunología; Antígeno CTLA-4/inmunología; Inmunotoxinas/inmunología; Receptor de Muerte Celular Programada 1/inmunología; Receptores OX40/inmunología; Animales; Femenino; Proteínas Ligadas a GPI/inmunología; Mesotelina; Ratones; Ratones Endogámicos BALB C

Palabras clave

Anti-drug antibodies; Check point inhibitor; Immune modulation; Immune-oncology; Immunogenicity; Immunotoxin

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunotoxinas / Receptores OX40 / Antígeno B7-H1 / Antígeno CTLA-4 / Receptor de Muerte Celular Programada 1 / Anticuerpos Monoclonales Límite: Animals Idioma: En Revista: Cell Immunol Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google